P/B
1,2
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
$271.6M
Market Cap • 9/25/2026
2017
(9 years)
Founded
2023
(3 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
3
EPS
—
Market Cap
Market Cap
271,6M
EV
66,7M
EV/Revenue
0
EV/EBITDA
-0,7
EV/EBIT
-0,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-66,7%
Total Yield
-66,7%
Payout
0%
Retained Earnings
-426,2M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
113%
Capex/OCF
-0,4%
SBC/OCF
—
% PPE
3,1%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
2,2
Debt/Equity
0%
Current Ratio
13,9
Quick Ratio
13,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!